Synthesis, characterization, molecular docking, in silico ADME study, and in vitro cytotoxicity evaluation of new pyridine derivatives of nabumetone.


  • Bushra K. Jameel Department of pharmaceutical chemistry, College of pharmacy, Mustansiriyah university
  • Ayad Mohammed Rasheed Raauf Al-Farahidi University, college of pharmacy
  • Wassan Abdul Kareem Abbas Department of Clinical Laboratories sciences, College of Pharmacy, Mustansiriyah university



Nabumetone, EGFR inhibitor, cyanopyridine, anticancer, molecular docking


New pyridine derivatives of nabumetone containing 2-amino 3-cyano moieties were synthesized and aimed to introduce new EGFR kinase inhibitors through two methods either by synthesis of chalcone derivatives initially (1a-d)

followed by reacting it with malononitrile and ammonium acetate to form (2a-d) or from a one-pot synthesis of all reactants together to synthesis compounds (2a-e). Melting point, and FT-IR spectra were used to characterize all the synthesized compounds and were confirmed by 1H-NMR, and 13C-NMR spectroscopy. The final compounds (2a-e) were investigated in vitro against A549 (lung cancer cell line) and WRL68 (human normal cell line). compounds (2a, 2b, and 2e) produced marked cytotoxic activity with IC50 (24.62, 23.43, and 24.06 μg/ml) respectively, higher than what obtained from erlotinib with IC50 (25 μg/ml) as a reference drug. Measuring the selectivity index (SI) reveals that all the compounds have high selectivity especially compound (2a) being the most selective towards cancerous cells rather than normal cells with SI two folds higher than erlotinib. The molecular docking study reveals good binding to the EGFR kinase that has a good correlation to the MTT Assay results. In silico ADME study exposes that this synthesized series not only have interesting activity but also shows promised pharmacokinetic properties.


- Dawood DH, Srour AM, Saleh DO, Huff KJ, Greco F, Osborn HMI. New pyridine and chromene scaffolds as potent vasorelaxant and anticancer agents. RSC Adv. 2021;11 (47):29441–52.

- Alfarouk KO, Stock CM, Taylor S, Walsh M, Muddathir AK, Verduzco D, et al. Resistance to cancer chemotherapy: Failure in drug response from ADME to P-gp. Cancer Cell Int. 2015;15(1):1–13.

- da Cunha Santos G, Shepherd FA, Tsao MS. EGFR Mutations and Lung Cancer. Annu Rev Pathol Mech Dis. 2011;6(1):49–69.

- Nam Y, Hwang D, Kim N, Seo HS, Selim KB, Sim T. Identification of 1 H-pyrazolo[3,4-b]pyridine derivatives as potent ALK-L1196M inhibitors. J Enzyme Inhib Med Chem. 2019;34 (1):1426–38.

- Clemow DB, Johnson KW, Hochstetler HM, Ossipov MH, Hake AM, Blumenfeld AM. Lasmiditan mechanism of action – review of a selective 5-HT1F agonist. J Headache Pain. 2020;21(1):71.

- Tsai RS, Carrupt PA, Tayar N El, Giroud Y, Andrade P, Testa B, et al. Physicochemical and Structural Properties of Non-Steroidal Anti-inflammatory Oxicams. Helv Chim Acta. 1993;76(2):842–54.

- Lei H, Kim JH, Son S, Chen L, Pei Z, Yang Y, et al. Immunosonodynamic Therapy Designed with Activatable Sonosensitizer and Immune Stimulant Imiquimod. ACS Nano. 2022;16(7) :10979–93.

- Najjar A, Karaman R. The prodrug approach in the era of drug design. Expert Opin Drug Deliv. 2019 ;16(1):1–5.

- AbdelHaleem A, Mansour AO, AbdelKader M, Arafa RK. Selective VEGFR-2 inhibitors: Synthesis of pyridine derivatives, cytotoxicity and apoptosis induction profiling. Bioorg Chem. 2020;103:104222.

- Abdel-Rahman AAH, Shaban AKF, Nassar IF, EL-Kady DS, Ismail NSM, Mahmoud SF, et al. Discovery of New Pyrazolopyridine, Furopyridine, and Pyridine Derivatives as CDK2 Inhibitors: Design, Synthesis, Docking Studies, and Anti-Prolifera-tive Activity. Molecules. 2021;26(13) :3923.

- Hosseinzadeh Z, Razzaghi-ASL N, Ramazani A, Aghahosseini H, Ramazani A. Synthesis, cytotoxic assessment, and molecular docking studies of 2,6-diaryl-substituted pyridine and 3,4- dihydropyrimidine-2(1H)-one scaffolds. TURKISH J Chem. 2020;44(1):194–213.

- R SA, Walmik P. Synthesis , antimicrobial and antioxidant activities of some indole analogues containing naphthyridine and pyrimi-donaphthyridine systems. 2012;51: 1593–606.

- Achagar R, Elmakssoudi A, Thoume A, Dakir M, Elamrani A, Zouheir Y, et al. Nanostructured Na2CaP2O7: A New and Efficient Catalyst for One-Pot Synthesis of 2-Amino-3-Cyanopyridine Derivatives and Evaluation of Their Antibacterial Activity. Appl Sci. 2022;12(11):5487.

- Atla SR, Nagireddy NR, Yejella RP. Anti-inflammatory, Analgesic and Antimicrobial activity studies of novel 4,6-disubstituted-2-amino-3-cyanopyridines. 2014;1(1):51–62.

- Karim HA, Raauf MR, Ali KF. Synthesis and Preliminary Pharmacological Evaluation of Some New Triazole Derivatives Bearing Nabumetone Moiety Targeting Cycl-ooxygenase Enzyme. 2021;12(1):190–5.

- Ismail MMF, Farrag AM, Harras MF, Ibrahim MH, Mehany ABM. Apoptosis: A target for anticancer therapy with novel cyanopyridines. Bioorg Chem. 2020;94:103481.

- Freshney RI. Culture of animal cells: a manual of basic technique and specialized applications. New Jersey: John Wiley & Sons; 2015.

- Jones G, Willett P, Glen RC, Leach AR, Taylor R. Development and validation of a genetic algorithm for flexible docking 1 1Edited by F. E. Cohen. J Mol Biol. 1997;267(3):727–48.

- Hanyzewski G, Mull M. HERMES: a tool kit for developing distributed modelling applications. Nanotechn-ology. 1996;7(3):193–6.

- Alawad KM, Mahdi MF, Raauf AMR. Molecular Docking study , and In vitro Evaluation of Antitumor Activity of Some New Isoxazoline and Pyrazoline Derivatives of Nabumet-one against breast cancer cell line (MCF-7). Al Mustansiriyah J Pharm Sci. 2022;2(3):24–34.

- Abourehab MAS, , Alaa M. Alqahtani BGMY and AMG. Globally Approved EGFR Inhibitors: Insights into Their Syntheses, Target Kinases, Biological Activities, Receptor Interactions, and Metabolism. Molecules. 2021;26(21):6677.

- Park JH, Liu Y, Lemmon MA, Radhakrishnan R. Erlotinib binds both inactive and active conformations of the EGFR tyrosine kinase domain. Biochem J. 2012;448(3):417–23.

- Raauf AMR, Omar TNA, Mahdi MF, Fadhil HR. Synthesis, molecular docking and anti-inflammatory evaluation of new trisubstituted pyrazoline derivatives bearing benze-nesulfonamide moiety. Nat Prod Res. 2022;1–8.

- Daina A, Michielin O, Zoete V. SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep. 2017;7:1–13.

- Mazen Mohammed Jwaid, Karima Fadhil Ali, Mayada Hadi Abd-alwahab. Synthesis, Antibacterial study and ADME Evaluation of Novel Isonicotinoyl Hydrazide Derivative Containing 1,3,4-Oxadiazole Moiety. Al Mustansiriyah J Pharm Sci. 2022;20(4):113–21.

- Prayong P, Barusrux S, Weerap-reeyakul N. Cytotoxic activity screening of some indigenous Thai plants. Fitoterapia. 2008;79(7–8):598–601.

- Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 2012;64